الفهرس 
BCG VaccineOnly 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
Today, BCG (bacille Calmette–Guérin) vaccine is administered worldwide to prevent severe forms of tuberculosis and is recommended for routine use at birth in countries with high tuberculosis prevalence. It is considered to have an excellent safety profile with rare serious complications.
BCG vaccine is live vaccine derived from a strain of Mycobacterium bovis that was attenuated by Calmette and Guerin at the Pasteur Institute and it is administered by the intradermal method.
All currently used vaccines differ in their ability to induce an immune response to tuberculin.
On average, BCG vaccine significantly reduces the risk of TB by around 65%. Protection is observed across many populations. Protection against tuberculous death, meningitis, and disseminated disease had ranged from 52% to 100%.This percentage is higher than percentage of protection against pulmonary TB which ranged from 2% to 80%.
BCG vaccine efficacy is higher in persons who were vaccinated during childhood compared with persons vaccinated at older ages.